Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

Marla Black Morgan, MD, with Phoebe Neurology Associates, presented findings on a study into the diagnostic journey of ...

Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

Furthermore, there was no history of thyroid disease, and her current thyroid function ... or psychological factors contributing to myasthenia gravis cannot be completely excluded. This case ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a ...